Pharmacokinetic ‐pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients

ConclusionsIn patients with stable CAD or a history of MI, near maximal platelet inhibition is achieved with both ticagrelor 60 and 90 mg twice daily. At modeled doses below 60mg, the response is overall reduced, more variable between patients, and patients will display greater peak ‐to‐trough variability.

https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.13812?af=R

Source: British Journal of Clinical Pharmacology - November 10, 2018 Category: Drugs & Pharmacology Authors: Magnus Åstrand, Carl Amilon, Daniel Röshammar, Anders Himmelmann, Dominick J. Angiolillo, Robert F. Storey, Paul A. Gurbel, Marc P. Bonaca, Bengt Hamrén Tags: ORIGINAL ARTICLE Source Type: research